Page 467 - Read Online
P. 467
Page 6 of 14 Saadi et al. Vessel Plus 2020;4:41 I http://dx.doi.org/10.20517/2574-1209.2020.54
Figure 1. Sentinel cerebral protection system. Image provided courtesy of Boston Scientific. © 2020 Boston Scientific Corporation or its
affiliates. All rights reserved
Figure 2. Sentinel implantation
Regardless of the fact that none of these trials have, individually, demonstrated superiority in terms of hard
outcomes, such as stroke and mortality, recent meta-analyzes showed that CEPD use was associated with
lower rates of stroke and 30-day mortality [18,23] . A propensity-matched patient cohort including 533 patients
also showed lower rates of procedural all-stroke (1.88% vs. 5.44%, OR = 0.35, 95%CI: 0.17-0.72, relative risk
reduction 65%; P = 0.0028), and the combined endpoint of all-cause mortality and all-stroke (2.06% vs.
